Sndl Inc. (SNDL) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Sndl Inc. (SNDL) stock forecast summary
On Oct. 16, 2026, SNDL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
Sndl Inc. is a small-cap company with a market capitalization of $322M. It ranks number 5 by market capitalization among the 29 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For SNDL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -29.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SNDL included.
Follow SNDL freeSNDL price chart and AI forecast
How SNDL ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Sndl Inc. (SNDL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric. Statement values were filed in CAD and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | SNDL | Rank |
|---|---|---|
| Market Cap | $322M | 5/29 |
| Revenue/Share | $7.90 | – |
| FCF/Share | $0.06 | – |
Profitability & Margins
| Metric | SNDL | Rank |
|---|---|---|
| ROE | -47.1% | 14/16 |
| ROA | -38.8% | 19/25 |
| ROIC | -36.9% | 18/21 |
| Gross Margin | 22.5% | 19/23 |
| Operating Margin | -16.2% | 14/24 |
| Net Margin | -18.3% | 13/22 |
| EBT Margin | -17.6% | 15/25 |
Financial Health
| Metric | SNDL | Rank |
|---|---|---|
| Current Ratio | 4.88x | 5/29 |
| Quick Ratio | 3.50x | 4/26 |
| D/E Ratio | 0.21x | 15/17 |
| Financial Leverage | 1.21x | 15/17 |
| Working Capital | $260M | 5/29 |
Cash Flow
| Metric | SNDL | Rank |
|---|---|---|
| Operating Cash Flow | $37M | 3/30 |
| Free Cash Flow | $14M | 5/12 |
| Capital Spending | -$23M | 10/12 |
| FCF/Sales | 0.7% | 8/12 |
| CapEx/Sales | 1.1% | 9/12 |
Operational Efficiency
| Metric | SNDL | Rank |
|---|---|---|
| Asset Turnover | 2.12x | 2/17 |
| Fixed Assets Turnover | 18.7x | 5/17 |
Income Statement
| Metric | SNDL | Rank |
|---|---|---|
| Total Revenue | $2.03B | 1/18 |
| Operating Income | -$328M | 28/28 |
| Net Income | -$372M | 24/25 |
| R&D Expense | $1M | 6/9 |
Dividend & Shareholder Information
| Metric | SNDL | Rank |
|---|---|---|
| Shares Outstanding | 258M | – |
Balance Sheet Highlights (USD millions, converted from CAD)
| Total Current Assets | $328M | 33.7% of assets |
| Cash & Short-term Investments | $184M | 18.9% of assets |
| Inventory | $92M | 9.5% of assets |
| Total Liabilities | $171M | 17.6% of assets |
SNDL quarterly financials and insider trading
Sndl Inc. (SNDL) industry peers
Companies classified under the same SEC industry code as Sndl Inc. (Medicinal Chemicals & Botanical Products): 33 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SNDL Sndl Inc. | ▶ | $322M |
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| TRLV Trulieve Cannabis Corp. | ▲ | $1.93B |
| CRON Cronos Group Inc. | ▶ | $1.18B |
| TLRY Tilray Brands, Inc. | ▼ | $414M |
| CGC Canopy Growth Corp | ▶ | $302M |
| GLAS Glass House Brands Inc. | ▼ | $301M |
| USNA Usana Health Sciences Inc | ▼ | $287M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| MDWD Mediwound Ltd. | ▶ | $152M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $80M |
| FTLF Fitlife Brands, Inc. | ▲ | $79M |
| BTMD Biote Corp. | ▲ | $35M |
| RAPH Raphael Pharmaceutical Inc. | ▼ | $30M |
| CHUC Charlie's Holdings, Inc. | ▼ | $27M |
| MRMD Marimed Inc. | ▲ | $24M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $9M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| BON Bon Natural Life Ltd | ▶ | $7M |
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| CYAN Cyanotech Corp | ▲ | $5M |
| IMCC Im Cannabis Corp. | ▼ | $2M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $290K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▶ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
Where SNDL sits on the market map
Sndl Inc. (SNDL) stock news
Loading...
Sndl Inc. (SNDL) stock forecast FAQ
What is the Sndl Inc. (SNDL) stock forecast?
On Oct. 16, 2026, SNDL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Sndl Inc. stock predictions?
For SNDL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -29.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 3.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Sndl Inc. forecasts updated?
Sndl Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Sndl Inc.'s industry peers?
33 issuers in our coverage, SNDL included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Canopy Growth Corp (CGC), Glass House Brands Inc. (GLAS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.